Key Highlights
- Total net revenues rose 22.5% year over year to RMB1.02 billion (US$148.0 million) for the quarter ended March 31, 2026, as a 58.5% jump in Skincare Brands revenue offset a 5.0% decline in Color Cosmetics Brands.
- Gross margin improved to 80.2% from 79.1%, but expenses rose faster than revenue, widening the GAAP operating loss to RMB99.0 million and the non-GAAP operating loss to RMB84.6 million.
- Yatsen closed the first tranche of a US$120 million convertible note placement with Trustar Capital, Hillhouse and founder Jinfeng Huang on May 21, 2026, alongside an active US$30 million buyback.
- Yatsen's strategy centers on "strengthening our R&D-led innovation, expanding our hero product families, and positioning our core brands for high-quality growth," in CEO Jinfeng Huang's words: continued investment behind Galenic, DR.WU and Eve Lom, plus capital from the Trustar Capital and Hillhouse-backed notes, earmarked for supply chain integration, overseas expansion and acquisitions.
Yatsen Holding Limited (NYSE:YSG), owner of Perfect Diary and a growing stable of premium skincare brands, posted 22.5% first-quarter 2026 revenue growth as Galenic, DR.WU and Eve Lom offset a decline in color cosmetics. Gross margin expanded to 80.2%, but heavier marketing spend widened both GAAP and non-GAAP operating losses even as the company raised fresh capital.
Why Yatsen Is Back on Investors' Radar
Yatsen Holding Limited (YSG) has spent the past two years arguing that its pivot from mass-market color cosmetics toward premium skincare is more than a defensive maneuver. Its May 26, 2026 first-quarter release gave that thesis its clearest support yet, with total net revenues climbing 22.5% year over year to RMB1.02 billion (US$148.0 million), inside management's prior guidance range.
The composition matters more than the headline. Net revenues from Yatsen's Skincare Brands, defined as Galenic, DR.WU's mainland China business, Eve Lom and other skincare labels, surged 58.5% to RMB574.2 million (US$83.2 million), lifting skincare's share of revenue to 56.2% from 43.5% a year earlier. CFO Donghao Yang said the combined net revenues of Galenic, DR.WU and Eve Lom grew 61.4%, calling it evidence of "the structural health of our business model." Color Cosmetics Brands declined 5.0%, a sign the legacy franchise is still shrinking as skincare fills the gap.
From Perfect Diary to a Multi-Brand Skincare Group
Founded in 2016 and listed on the NYSE in November 2020, Yatsen built its early identity around Perfect Diary, a cosmetics brand that captured Chinese demand for accessibly priced, digitally marketed makeup. That single-category model proved volatile once online beauty spending cooled and Douyin traffic costs climbed, prompting a pivot toward acquired skincare brands at higher price points: French prestige label Galenic, Taiwanese clinical brand DR.WU and British luxury house Eve Lom. Yatsen is a Cayman Islands holding company that, per its April 2026 Form 20-F, runs a small portion of operations through variable interest entity arrangements contributing 3.1% of third-party revenues in 2025.
The Skincare Pivot, Framed Around Yatsen
The clearest catalyst for Yatsen (YSG) is the pace at which premium skincare is scaling relative to the legacy cosmetics business. Skincare's rise from 43.5% to 56.2% of revenue in a single year reflects a deliberate reallocation of spending toward Galenic, DR.WU and Eve Lom. That carries a cost: R&D expenses rose to RMB39.4 million from RMB22.6 million on higher headcount, while marketing expenses jumped to RMB737.2 million from RMB553.8 million, partly on "higher traffic acquisition costs on the Douyin platform." Whether skincare can generate the operating leverage Perfect Diary never achieved is the open question for Yatsen (YSG).
First-Quarter 2026 Performance in Detail
Gross profit increased 24.3% to RMB819.2 million (US$118.8 million), and gross margin expanded to 80.2% from 79.1%. Operating expenses grew faster, up 32.5% to RMB918.1 million, or 89.9% of revenue versus 83.2% a year earlier.
That produced a GAAP operating loss of RMB99.0 million (US$14.3 million), versus RMB34.1 million previously. Non-GAAP operating loss, excluding share-based compensation and acquisition amortization, was RMB84.6 million (US$12.3 million), versus RMB14.9 million. Net loss was RMB61.9 million (US$9.0 million), or RMB0.64 per diluted ADS, versus RMB5.6 million previously; non-GAAP net loss was RMB57.3 million (US$8.3 million), reversing RMB7.1 million of non-GAAP net income, or RMB0.60 per diluted ADS (each ADS equals twenty Class A shares). Second-quarter guidance calls for revenues of RMB1.20 billion to RMB1.30 billion, implying 10% to 20% growth, a deceleration from the first quarter's pace.
Cash Position, Financing and Capital Return
As of March 31, 2026, Yatsen held cash, restricted cash and short-term investments of RMB934.2 million (US$135.4 million), down from RMB1.05 billion at year-end 2025. Net cash used in operations was RMB90.0 million, versus RMB23.8 million generated a year earlier.
On March 11, 2026, Yatsen agreed to issue approximately US$120 million of convertible notes and warrants to a vehicle affiliated with Trustar Capital and founder Jinfeng Huang, co-investing personally; on May 21, 2026, it disclosed Hillhouse, a shareholder since 2018, had joined the vehicle and closed the first of two tranches. The notes carry a 1.5% coupon and a $4.63 ADS conversion price, with proceeds earmarked for R&D, supply chain integration and expansion. Separately, the board approved a new US$30 million buyback on May 16, 2025, succeeding a program under which Yatsen repurchased roughly 39.8 million ADSs for approximately US$199.9 million between November 2021 and May 2025.
Where Growth Could Come From Next
Yatsen's strategy centers on "strengthening our R&D-led innovation, expanding our hero product families, and positioning our core brands for high-quality growth," in CEO Jinfeng Huang's words: continued investment behind Galenic, DR.WU and Eve Lom, plus capital from the Trustar Capital and Hillhouse-backed notes, earmarked for supply chain integration, overseas expansion and acquisitions. Yatsen has not disclosed specific markets or targets, so expansion is an intention rather than a confirmed catalyst. CFO Donghao Yang's remarks on "cost optimization to ensure that our top-line expansion efficiently translates into future margin improvement" suggest narrowing the growth-profitability gap is management's next milestone.
Material Risks Facing Yatsen's Turnaround
The most immediate risk is execution: operating and net losses widened even as revenue grew, meaning skincare has not yet produced the operating leverage needed for profitability. Marketing expenses, already 72.2% of revenue, are sensitive to rising Douyin traffic costs.
Competitive intensity is a risk Yatsen flags itself, describing the beauty industry as "highly competitive." Chinese consumer demand has swung between double-digit growth and outright declines in recent periods, so the current skincare-led phase is not guaranteed to persist.
As a Cayman Islands company with China operations, Yatsen is also exposed to the Holding Foreign Companies Accountable Act. Its 2025 20-F states ADSs "may be prohibited from trading in the United States under the HFCAA in the future if the PCAOB is unable to inspect or investigate completely auditors located in China," noting PCAOB access has historically been constrained.
Outlook
The bull case: skincare brands now generate the majority of revenue, gross margin keeps expanding, and fresh capital has come from long-term holders Hillhouse and Trustar Capital rather than dilutive offerings. The base case: second-quarter guidance implies decelerating growth, and both GAAP and non-GAAP losses widened even as revenue accelerated. The downside case centers on intensifying competition, volatile Chinese consumer demand, rising marketing costs and unresolved China-related regulatory risk. This article makes no prediction about where Yatsen's share price will trade.
Conclusion
Yatsen Holding Limited's (YSG) first-quarter 2026 results confirm its shift toward premium skincare brands Galenic, DR.WU and Eve Lom now drives the majority of revenue and keeps lifting gross margin. What the quarter did not deliver was profitability: GAAP and non-GAAP operating and net losses widened as marketing and R&D spending increased. With fresh capital from Trustar Capital and Hillhouse closing alongside an active buyback, Yatsen has liquidity to keep investing, but whether that spending converts skincare-led growth into sustainable earnings remains the key question for the rest of 2026.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_40_422713.jpg)


Please wait processing your request...